{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:20:16Z","timestamp":1784816416510,"version":"3.55.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>T-cell acute lymphoblastic leukemia (T-ALL) is a hematologic tumor, characterized by several genetic alterations, that constitutes 15% of pediatric and 25% of adult ALL. While with current therapeutic protocols children and adults\u2019 overall survival (OS) rates reach 85\u201390% and 40\u201350%, respectively, the outcome for both pediatric and adult T-ALL patients that relapse or are refractory to induction therapy, remains extremely poor, achieving around 25% OS for both patient groups. About 60% of T-ALL patients show increased NOTCH1 activity, due to activating <jats:italic>NOTCH1<\/jats:italic> mutations or alterations in its ubiquitin ligase <jats:italic>FBXW7<\/jats:italic>. NOTCH signaling has been shown to contribute to chemotherapy resistance in some tumor models. Hence, targeting the NOTCH1 signaling pathway may be an effective option to overcome relapsed and refractory T-ALL.<\/jats:p><jats:p>Here, we focused on the therapeutic activity of the NOTCH1-specific monoclonal antibody OMP-52M51 in combination either with drugs used during the induction, consolidation, or maintenance phase in mice xenografts established from pediatric and adult relapsed <jats:italic>NOTCH1<\/jats:italic> mutated T-ALL samples. Interestingly, from RNAseq data we observed that anti-NOTCH1 treatment in vivo affects the purine metabolic pathway. In agreement, both in vitro and in vivo, the greatest effect on leukemia growth reduction was achieved by anti-NOTCH1 therapy in combination with antimetabolite drugs. This result was further corroborated by the longer life span of mice treated with the anti-NOTCH1 in combination with antimetabolites, indicating a novel Notch-targeted therapeutic approach that could ameliorate pediatric and adult T-ALL patients outcome with relapse disease for whom so far, no other therapeutic options are available.<\/jats:p>","DOI":"10.1186\/s40164-023-00439-6","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T07:02:53Z","timestamp":1693810973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Targeting NOTCH1 in combination with antimetabolite drugs prolongs life span in relapsed pediatric and adult T-acute lymphoblastic leukemia xenografts"],"prefix":"10.1186","volume":"12","author":[{"given":"Sonia","family":"Minuzzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Agnusdei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marica","family":"Pinazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana A.","family":"Amaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Sacchetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Bertorelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orietta","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Serafin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Indraccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"key":"439_CR1","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","volume":"371","author":"CH Pui","year":"2008","unstructured":"Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371:1030\u201343.","journal-title":"Lancet"},{"issue":"12","key":"439_CR2","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1038\/leu.2014.142","volume":"28","author":"CH Pui","year":"2014","unstructured":"Pui CH, Pei D, Campana D, et al. A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia. 2014;28(12):2336\u201343.","journal-title":"Leukemia"},{"key":"439_CR3","doi-asserted-by":"crossref","unstructured":"Rowe JM, Buck G, Burnett AK et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993. Blood. 2005 1;106(12):3760-7.","DOI":"10.1182\/blood-2005-04-1623"},{"issue":"4","key":"439_CR4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/j.1365-2141.2008.07499.x","volume":"144","author":"B Reism\u00fcller","year":"2009","unstructured":"Reism\u00fcller B, Attarbaschi A, Peters C, et al. Austrian Berlin-Frankfurt-M\u00fcnster (BFM) Study Group. Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria\u2013a population-based report of the austrian Berlin-Frankfurt-M\u00fcnster (BFM) Study Group. Br J Haematol. 2009;144(4):559\u201370.","journal-title":"Br J Haematol"},{"key":"439_CR5","doi-asserted-by":"crossref","unstructured":"Einsiedel HG, von Stackelberg A, Hartmann R et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-M\u00fcnster Group 87. J Clin Oncol. 2005;1;23(31):7942-50. Erratum in: J Clin Oncol. 2008;1;26(13):2238.","DOI":"10.1200\/JCO.2005.01.1031"},{"issue":"9","key":"439_CR6","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1182\/blood.V84.9.3105.3105","volume":"84","author":"MB Diccianni","year":"1994","unstructured":"Diccianni MB, Yu J, Hsiao M, Mukherjee S, Shao LE, Yu AL. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood. 1994;84(9):3105\u201312.","journal-title":"Blood"},{"issue":"5694","key":"439_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1126\/science.1102160","volume":"306","author":"AP Weng","year":"2004","unstructured":"Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(5694):269\u201371.","journal-title":"Science"},{"key":"439_CR8","doi-asserted-by":"crossref","unstructured":"O\u2019Neil J, Grim J, Strack P, Rao S et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 2007; 6;204(8):1813-24.","DOI":"10.1084\/jem.20070876"},{"issue":"2","key":"439_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/leu.2013.183","volume":"28","author":"V Agnusdei","year":"2014","unstructured":"Agnusdei V, Minuzzo S, Frasson C, et al. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. Leukemia. 2014;28(2):278\u201388.","journal-title":"Leukemia"},{"issue":"1","key":"439_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/carcin\/bgu223","volume":"36","author":"S Minuzzo","year":"2015","unstructured":"Minuzzo S, Agnusdei V, Pusceddu I, et al. DLL4 regulates NOTCH signaling and growth of T acute lymphoblastic leukemia cells in NOD\/SCID mice. Carcinogenesis. 2015;36(1):115\u201321.","journal-title":"Carcinogenesis"},{"issue":"28","key":"439_CR11","doi-asserted-by":"publisher","first-page":"16292","DOI":"10.1073\/pnas.1922606117","volume":"14","author":"R Lehal","year":"2020","unstructured":"Lehal R, Zaric J, Vigolo M, et al. Pharmacological disruption of the notch transcription factor complex. Proc Natl Acad Sci U S A. 2020;14(28):16292\u2013301.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"439_CR12","doi-asserted-by":"publisher","first-page":"Abstract968","DOI":"10.1182\/blood.V124.21.968.968","volume":"121","author":"PDD Zweidler-McKay","year":"2014","unstructured":"Zweidler-McKay PDD, Douer D. The safety and activity of BMS- 906024, a gamma secretase inhibitor (GSI) with anti-notch activity, in patients with relapsed T-cell acute lymphoblastic leukemia (T-ALL): initial results of a phase I trial. Blood. 2014;121(21):Abstract968.","journal-title":"Blood"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-023-00439-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-023-00439-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-023-00439-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T19:07:57Z","timestamp":1700507277000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-023-00439-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["439"],"URL":"https:\/\/doi.org\/10.1186\/s40164-023-00439-6","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]},"assertion":[{"value":"22 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Procedures involving animals conformed to current laws and policies (EEC Council Directive 2010\/63\/EU, OJ L 276, 20.10.2010) were authorized by the Italian Ministry of Health (894\/2016-PR).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"76"}}